{"nctId":"NCT02237950","briefTitle":"Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)","startDateStruct":{"date":"2014-10-13","type":"ACTUAL"},"conditions":["Bacterial Vaginosis"],"count":586,"armGroups":[{"label":"1% SPL7013 Gel","type":"EXPERIMENTAL","interventionNames":["Drug: Metronidazole oral tablets 500mg","Drug: 1% SPL7013 Gel"]},{"label":"Placebo Gel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Metronidazole oral tablets 500mg","Drug: Placebo gel"]}],"interventions":[{"name":"Metronidazole oral tablets 500mg","otherNames":[]},{"name":"1% SPL7013 Gel","otherNames":["VivaGel","astodimer sodium"]},{"name":"Placebo gel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Current active episode of BV (diagnosis defined as: At least 3 of the 4 Amsel criteria; Nugent score of at least 4; presence of BV-related symptoms)\n* History of recurrent BV (at least 3 episodes in previous year including current episode)\n* Using an effective method of contraception\n\nExclusion Criteria:\n\n* Test positive for a sexually transmitted infection\n* Presence of genital Herpes Simplex Virus (HSV) lesions or Human Papilloma Virus (HPV) lesions requiring treatment\n* Abnormal pelvic exam, including presence of other vaginal or urinary tract infections\n* Pregnancy","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"16 Years","maximumAge":"45 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Recurrence of BV Where a Diagnosis of BV is Defined as the Presence of at Least 3 Clinical Findings","description":"Number of participants with a recurrence of BV, where a diagnosis of BV is defined as the presence of at least 3 clinical findings (Amsel criteria)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"158","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Recurrence of BV Where a Diagnosis of BV is Defined as the Presence of at Least 3 Clinical Findings","description":"Time to recurrence of BV (days), where a diagnosis of BV is defined as the presence of at least 3 clinical findings (Amsel criteria)","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrence of Patient-reported BV Symptoms","description":"Number of participants with self-reported BV symptoms (vaginal discharge and/or odor)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrence of Individual Amsel Criteria","description":"Number of participants with positive individual Amsel criterion\n\n\\- Clue cells representing at least 20% of total epithelial cells","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"132","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrence of BV as Determined by Presence of a Nugent Score of 7-10","description":"Number of participants with a recurrence of BV as determined by presence of a Nugent score of 7-10 (BV), where 0-3 is normal, and 4-6 is intermediate.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"135","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrence of BV Where a Diagnosis of BV is Defined as the Presence of at Least 3 Clinical Findings","description":"Number of participants with a recurrence of BV, where a diagnosis of BV is defined as the presence of at least 3 clinical findings (Amsel criteria)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"194","spread":null},{"groupId":"OG001","value":"213","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrence of BV According to the Composite Definition of at Least 3 Clinical Findings (Amsel Criteria) and a Nugent Score of 4-10.","description":"Number of participants with a recurrence of BV according to the composite definition of at least 3 clinical findings (Amsel criteria) and a Nugent score of 4-10 (intermediate to BV), where 0-3 is normal.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Brief Index of Sexual Functioning for Women Questionnaire Composite Score","description":"Change from baseline in brief index of sexual functioning for women (BISF-W) questionnaire composite score. The composite score includes scores from dimensions (D) of thoughts/desire (D1, 0-12), arousal (D2, 0-12), frequency of sexual activity (D3, 0-12), receptivity/initiation (D4, 0-12), pleasure (D5, 0-12), relationship satisfaction (D6, 0-12), and any problems affecting sexual functioning (D7, 0-16). The composite score is calculated as D1+D2+D3+D4+D5+D6-D7 with a range of -16 to +75. A positive change in composite score from baseline to Week 16 reflects an improvement in sexual functioning, with a greater change in score indicating a greater improvement in sexual functioning.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events (AEs)","description":"Number of participants with genitourinary AEs considered potentially related to study treatment","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":294},"commonTop":["Vulvovaginal candidiasis","UTI","Headache","Vulvovaginal mycotic infection","Nasopharyngitis"]}}}